Article
A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for the treatment of post kala-azar dermal leishmaniasis
2024-04-11
Abstract excerpt
<h4>Summary</h4> <h4>Background</h4> In a recent Phase IIa clinical trial, the candidate leishmaniasis vaccine ChAd63-KH was shown to be safe and immunogenic in Sudanese patients with post kala-azar dermal leishmaniasis (PKDL). However, its value as a stand-alone therapeutic was unknown. <h4>Methods</h4> To assess the therapeutic efficacy of ChAd63-KH, we conducted a “window of opportunity” randomized, double-b...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 66fb9ba7-a6db-5962-804c-6c8c5034e273
- DOI
- 10.1101/2024.04.11.24305597
